| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FCGR2A |
| Uniprot No | P12318 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 34-217aa |
| 氨基酸序列 | QAAAPPKAVLKLEPPWINVLQEDSVTLTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHSHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMG |
| 预测分子量 | 24.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FCGR2A重组蛋白的3篇示例文献及其摘要概括(注：内容为模拟虚构，仅作参考格式示例)：
1. **文献名称**：*Expression and Functional Characterization of Recombinant Human FCGR2A in Mammalian Cells*
**作者**：Smith A, et al.
**摘要**：研究通过哺乳动物表达系统(如HEK293细胞)成功表达并纯化FCGR2A重组蛋白，验证其与IgG抗体的结合活性，并证明其在体外免疫应答模型中的功能。
2. **文献名称**：*Structural Insights into FCGR2A Polymorphism and Ligand Binding Specificity*
**作者**：Zhang L, et al.
**摘要**：利用X射线晶体学解析FCGR2A重组蛋白的胞外结构域，揭示其H131R多态性对IgG亚类结合能力的影响，为自身免疫疾病易感性提供分子机制解释。
3. **文献名称**：*FCGR2A Recombinant Protein as a Therapeutic Target in Antibody-Dependent Enhancement of Viral Infection*
**作者**：Chen Y, et al.
**摘要**：探讨FCGR2A重组蛋白在登革热病毒抗体依赖性增强(ADE)中的作用，通过阻断实验表明其可能成为抑制病毒感染的潜在靶点。
4. **文献名称**：*Development of a High-Throughput Assay for FCGR2A-Mediated Phagocytosis Using Recombinant Protein*
**作者**：Johnson R, et al.
**摘要**：基于FCGR2A重组蛋白建立体外吞噬作用检测平台，用于筛选调节受体活性的小分子或抗体药物，推动免疫治疗研究。
(注：以上文献为示例，实际引用需查询真实数据库如PubMed、Web of Science等。)
FCGR2A (Fc gamma receptor IIa) is a transmembrane glycoprotein belonging to the immunoglobulin superfamily, primarily expressed on immune cells such as macrophages, neutrophils, and dendritic cells. It plays a critical role in mediating immune responses by binding to the Fc region of IgG antibodies, thereby linking antibody-mediated recognition to cellular effector functions like phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), and cytokine release. FCGR2A exists in two functionally distinct allelic variants (H131 and R131) due to a single nucleotide polymorphism (SNR), which influences its binding affinity to IgG subclasses and impacts disease susceptibility, including autoimmune disorders and infections.
Recombinant FCGR2A protein is engineered using biotechnological platforms, often expressed in mammalian cell systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, such as glycosylation. The recombinant form typically includes the extracellular domain of FCGR2A, enabling studies on receptor-ligand interactions without membrane-associated complexities. Purification techniques like affinity chromatography yield high-purity protein suitable for functional assays.
This recombinant protein is widely utilized in biomedical research to dissect Fcγ receptor signaling pathways, evaluate therapeutic monoclonal antibodies (e.g., optimizing IgG effector functions in cancer immunotherapy), and model immune complex-related diseases. It also serves as a tool for diagnostic development, such as screening autoimmune biomarkers or assessing receptor dysregulation in conditions like systemic lupus erythematosus (SLE) or rheumatoid arthritis. Additionally, recombinant FCGR2A supports drug discovery by enabling high-throughput screening of molecules targeting Fcγ receptors to modulate immune responses.
×
